Starter en tråd om Xbrane Biopharma AB (XBRANE.ST) siden en del har den i favoritt-listen eller i porteføljen sin 
Xbrane Biopharma AB (publ), a biopharmaceutical company, develops and manufactures biosimilars and generic long-acting injectables. The company’s lead product candidates under development include Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes related macular edema, and retinal vein occlusion; and Spherotide, a long-acting injectable with the active substance triptorelin for the treatment of prostate cancer, breast cancer, endometriosis, and myoma.
Its development stage products comprise Octreosphere for acromegaly and neuroendocrine tumors; Risperisphere for schizophrenia and bipolar disorders; Exenasphere for type-2 diabetes; Leuprosphere for advanced metastatic prostate cancer, endometriosis, and uterine fibroids; Xcimzane for rheumatoid and psoriatic arthritis, chrons disease, and ankylosis spondylitis; and Xoncane for acute lymphoblastic leukemia. Xbrane Biopharma AB (publ) is headquartered in Solna, Sweden.
La oss starte diskusjonen! @mermagi @Rockstock @greyboss @VargVemund @pdx